Cardiac Markers Clash For Hospital, Lab Space: Biosite Triages R&D Projects
This article was originally published in The Gray Sheet
Executive Summary
Biosite's pursuit of additional disease markers for its Triage immunoassay meter will continue unabated this summer, even as the company defends BNP test market share from newcomer Abbott Labs and imminent rival Dade Behring
You may also be interested in...
BioSite Triage Becomes The First BNP Test To Receive A CLIA Waiver
BioSite plans to market its Triage BNP test to the 55,000 physician practices that most often treat heart failure patients after becoming the first BNP test manufacturer to receive a CLIA waiver from FDA
BioSite Triage Becomes The First BNP Test To Receive A CLIA Waiver
BioSite plans to market its Triage BNP test to the 55,000 physician practices that most often treat heart failure patients after becoming the first BNP test manufacturer to receive a CLIA waiver from FDA
BioSite Launches Triage Stroke Panel In Europe, Defends BNP Test Share
BioSite's European launch of its Triage stroke panel comes as the firm faces increasing BNP test pricing pressure from Abbott Labs